Skip to content
by Legal Desire
19 July 2024

Latham & Watkins Advises Invetx in Acquisition by Dechra Pharmaceuticals

Advising firms

Deal team

22 lawyers named
LawyerFirmSeniorityPracticeOffice
Kristen Grannis Lead Latham & Watkins LLP Partner corporate Boston
Spencer Ricks Lead Latham & Watkins LLP Partner corporate Boston
Gloria Ring Lead Latham & Watkins LLP Counsel corporate Boston
Andrew Rondeau Latham & Watkins LLP Associate corporate Not stated
Christine Kalpin Latham & Watkins LLP Associate corporate Not stated
Josh Friedman Latham & Watkins LLP Partner benefits and compensation Boston
Tessa Young Latham & Watkins LLP Associate benefits and compensation Not stated
Grace Lee Latham & Watkins LLP Partner tax Bay Area
Dennis Poehland Latham & Watkins LLP Associate tax Not stated
Josh Holian Latham & Watkins LLP Partner antitrust Bay Area
Ian Conner Latham & Watkins LLP Partner antitrust Washington, D.C.
Patrick English Latham & Watkins LLP Partner antitrust Washington, D.C.
Ehson Kashfipour Latham & Watkins LLP Associate antitrust Not stated
Sarah Gagan Latham & Watkins LLP Partner intellectual property Boston
Eliot Choy Latham & Watkins LLP Counsel intellectual property New York
Arun Mohan Latham & Watkins LLP Associate intellectual property Not stated
Heather Deixler Latham & Watkins LLP Partner data privacy Bay Area
Mitch Bennett Latham & Watkins LLP Associate data privacy Not stated
Elizabeth Richards Latham & Watkins LLP Partner FDA regulatory Washington, D.C.
Meryl Bartlett Latham & Watkins LLP Associate FDA regulatory Not stated
Eveline Van Keymeulen Latham & Watkins LLP Partner EU regulatory Brussels
Jeanne Fabre Latham & Watkins LLP Associate EU regulatory Not stated

Stated terms

Stated value
USD 520m (US$520 million)
What the figure measures
Total transaction value
Client
Invetx, Inc.Sell-side
Counterparties
Dechra Pharmaceuticals Limited (Buy-side)